Treatment of Skin Papillomas with Topical α-Lactalbumin–Oleic Acid
Top Cited Papers
- 24 June 2004
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (26) , 2663-2672
- https://doi.org/10.1056/nejmoa032454
Abstract
We studied the effect on skin papillomas of topical application of a complex of α-lactalbumin and oleic acid (often referred to as human α-lactalbumin made lethal to tumor cells [HAMLET]) to establish proof of the principle that α-lactalbumin–oleic acid kills transformed cells but not healthy, differentiated cells. Forty patients with cutaneous papillomas that were resistant to conventional treatment were enrolled in a randomized, placebo-controlled, double-blind study, in which α-lactalbumin–oleic acid or saline placebo was applied daily for three weeks and the change in the volume of each lesion was recorded. After this first phase of the study, 34 patients participated in the second phase, an open-label trial of a three-week course of α-lactalbumin–oleic acid. Approximately two years after the end of the open-label phase of the study, 38 of the original 40 patients were examined, and long-term follow-up data were obtained. In the first phase of the study, the lesion volume was reduced by 75 percent or more in all 20 patients in the α-lactalbumin–oleic acid group, and in 88 of 92 papillomas; in the placebo group, a similar effect was evident in only 3 of 20 patients (15 of 74 papillomas) (P<0.001). After the patients in the initial placebo group had been treated with α-lactalbumin–oleic acid in the second phase of the study, a median reduction of 82 percent in lesion volume was observed. At follow-up two years after the end of the second phase, all lesions had completely resolved in 83 percent of the patients treated with α-lactalbumin–oleic acid, and the time to resolution was shorter in the group originally assigned to receive α-lactalbumin–oleic acid than among patients originally in the placebo group (2.4 vs. 9.9 months; P<0.01). No adverse reactions were reported, and there was no difference in the outcomes of treatment between immunocompetent and immunosuppressed patients. Treatment with topical α-lactalbumin–oleic acid has a beneficial and lasting effect on skin papillomas.Keywords
This publication has 19 references indexed in Scilit:
- Local treatments for cutaneous warts: systematic review * Commentary: Systematic reviewers face challenges from varied study designsBMJ, 2002
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002
- Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individualsJournal of Medical Virology, 2000
- VerrucasAmerican Journal of Clinical Dermatology, 2000
- HPV infections and immunosuppressionClinics in Dermatology, 1997
- Papillomavirus and HPV typingClinics in Dermatology, 1997
- Apoptosis induced by a human milk protein.Proceedings of the National Academy of Sciences, 1995
- Attempts to detect virus‐specific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virusInternational Journal of Cancer, 1974
- SKIN CANCER AND IMMUNOSUPPRESSIONThe Lancet, 1971
- "Crystalline" Virus-Like Particles from Skin Papillomas Characterized by Intranuclear Inclusion Bodies.Experimental Biology and Medicine, 1949